Marks Peter Ashley purchased 47,620 ALTERITY THERAPEUTICS LTD shares at $0.50 per share on August 31, 2026. The transaction matters to investors because it records a director’s direct share ownership and leaves Ashley holding 191,340 shares after the purchase, while the transaction record also references derivative securities.
Key Highlights
- The purchase price was $0.50 per ALTERITY THERAPEUTICS LTD share.
- Marks Peter Ashley held 191,340 shares after the transaction.
- The transaction record also lists 47,620 derivative securities at $0.50 per share.
Marks Peter Ashley, a director of ALTERITY THERAPEUTICS LTD (NASDAQ: ATHE), purchased 47,620 shares on August 31, 2026. The filing records the purchase at $0.50 per share.
Director Purchase Details
The transaction was classified under code P. Following the purchase, Ashley owned 191,340 ALTERITY THERAPEUTICS LTD shares. The record also lists 47,620 derivative securities acquired at $0.50 per share on the same date. Ashley’s resulting holding of derivative securities was none. The record lists the share and derivative-security transactions separately and states the post-transaction holdings for each category. Ashley is identified as a director of ALTERITY THERAPEUTICS LTD. The purchase date was August 31, 2026, and the listed price for both the shares and derivative securities was $0.50 per share.
FAQs
Q: How many ALTERITY THERAPEUTICS LTD shares did Peter Ashley buy?
A: Marks Peter Ashley bought 47,620 ALTERITY THERAPEUTICS LTD shares on August 31, 2026. The listed purchase price was $0.50 per share.
Q: What was Peter Ashley’s shareholding after the ATHE transaction?
A: Peter Ashley owned 191,340 ALTERITY THERAPEUTICS LTD shares after the transaction. He was identified as a director in the transaction record.
Q: Did the ATHE transaction include derivative securities?
A: Yes. The record lists 47,620 derivative securities acquired at $0.50 per share, while Ashley’s resulting holding of derivative securities was none after the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.